Aug 07, 2018 — TUCSON, Ariz., Aug. 7, 2018 /PRNewswire/ — Accelerate Diagnostics, Inc. announced today that it received an Innovative Technology contract from Vizient, Inc., the largest member-driven health care performance improvement company in the United States. The contract was based on a recommendation of the Accelerate Pheno™ system by hospital experts in this category who serve on […]

Continue reading

Aug 06, 2018 — Revenue up 142 Percent, Global install base up 25 Percent TUCSON, Ariz., Aug. 6, 2018 /PRNewswire/ — Accelerate Diagnostics, Inc. today announced financial results for the quarter ending June 30, 2018. The company posted revenue of $1.7 million, up 142% from the prior year quarter, and reported a record number of new agreements signed in […]

Continue reading

Jun 06, 2018 — Accelerate Diagnostics, Inc. announced today it will host symposia on the clinical opportunities of integrating fast, phenotypic susceptibility testing into antimicrobial stewardship programs and its impact on the management of patients with bacteremia at the American Society of Microbiologist Microbe 2018 forum in Atlanta, Georgia.

Continue reading

May 10, 2018 — Accelerate Diagnostics, Inc. today announced financial results for the quarter ending March 31, 2018. The company generated revenue of $801,000, up 51% from the prior year, and reported signed agreements for 345 instruments.

Continue reading

Over the past several years, Accelerate Diagnostics, together with our scientific collaborators, conducted numerous scientific studies supporting the exciting capabilities of our ID/AST System. Many of these studies resulted in posters presented at international conferences and peer-reviewed publications. We have conducted over 87,000 internal identification and susceptibility experiments across a panel of more than 20 of the most clinically prevalent species in sample types such as positive blood cultures and BALs. These studies demonstrated compelling performance versus reference and comparator methods, the results of which have been consistently duplicated by our clinical research partners. Below you will find links to some of these posters and publications.

These publications may include information from one or more organism/antimicrobial combinations that are research use only and not for use in diagnostic procedures.

Certain uses of devices included in these publications may not have been approved or cleared by the U.S. Food and Drug Administration or other regulatory bodies.

See product labeling for instructions for use, warnings, and limitations specific to each product and region.